RealiseD: Realising Clinical trials in Ultra-Rare diseases
This webinar took place on January 13th, 2026, and spotlighted how RealiseD pioneered a collaborative, end‑to‑end approach to clinical trials in ultra‑rare diseases. During the session, we guided participants through the project’s objectives, structure, and methodologies—and showcased how they could contribute to this transformative movement.
This interactive session:
- Explored the unique challenges of conducting trials in ultra‑rare diseases
- Ignited early‑stage collaboration among stakeholders
- Identified current obstacles and uncovered practical, actionable solutions
- Aligned participants around shared principles for interpreting URD data
“Insights matter—don’t miss this chance to influence the next generation of clinical research in ultra-rare conditions!”
Watch the webinar!
Agenda
Introduction – by Kathy Williams, Executive Director, Global Regulatory Affairs, AstraZeneca, and RealiseD project lead
Presentation – by Ralf-Dieter Hilgers, Professor at SFU and RealiseD coordinator
Discussion Pannel
Solange Corriol – Independent consultant in Regulatory Affairs and Policy
Donato Bonifazi – CEO of Consorzio per Valutazioni Biologiche e Farmacologiche
Helene Le Borgne – Policy Officer at European Commission
Audience Q&A
Closure
About RealiseD
RealiseD is an Innovative Health Initiative lead y Sigmund Freud Private University and AstraZeneca that unites nearly 40 partners from academia, regulatory bodies, clinical research institutes and hospitals, patient organisations, pharmaceutical companies or European Research Infrastructures to establish new gold standards for clinical trials in rare and ultra-rare diseases.
